Stock Analiz

MDxHealth SA MDXH

Medical Specialities · IPO 2021 · data as of November 13, 2026

$0.14Market cap $14M
Open the interactive analysis →

MDxHealth SA (MDXH) is a healthcare company listed in the US with a market value of about $14M. In the twelve months to June 30, 2026 it had revenue of $114M and net income of -$37M, a net margin of -32.7%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is financial health (0/5).

Key numbers: 5-year revenue growth of 42% a year, a 5-year average ROIC of -49%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 26% above the current price.

About MDxHealth SA

MDxHealth SA is listed in the US and classified in medical specialities, IPO year 2021. Revenue went from $12M in 2019 to $108M in 2025, growth of about 44.6% a year. It was profitable in 0 of the last 7 years in our data.

Score: 1.4 / 5

Value1/5
Future growth3/5
Track record2/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.1
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-43.8%
Shareholder yield0.0%
Intrinsic value vs. price+26%

Growth and quality

Revenue growth (1 yr)19.8%
Revenue growth (5 yrs, per year)42.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-76.8%
ROIC (5-yr avg.)-48.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$114M$108M$90M$70M$37M$22M$18M$12M
Net income-$37M-$34M-$38M-$43M-$44M-$29M-$29M-$43M
Free cash flow-$6M-$3M-$20M-$24M-$37M-$23M-$21M-$22M
EPS (diluted)$-0.70$-0.35$-0.40$-0.45$-0.46$-0.30$-0.30$-0.45
Net margin-32.7%-31.1%-42.3%-61.4%-118.9%-130.4%-155.3%-365.7%
ROIC—-21.3%-29.7%-50.5%-85.7%-57.2%-463.7%-216.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $0.83, 478% above the current price; targets range from $0.50 to $1.00; the consensus rating is “Hold”; expected EPS is $-0.46 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is MDxHealth SA stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 26% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does MDxHealth SA pay a dividend?

Not currently.

Is MDxHealth SA a good stock to buy?

We do not give buy or sell advice. MDxHealth SA scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.